PARP1 and Alzheimer disease: Pharmacological induction of autophagy by carbamazepine, trehalose, spermidine, and rapamycin, amongst others and boosting NAD+ levels by NAM, NR or NMN improve cognitive function in AD mouse models; SIRT1 activation or PARP1 inhibition is protective in cell and animal models of AD; ongoing clinical trials with NAD+ precursors, such as NR (NCT05617508; NCT04430517) or NMN (NCT05040321) are assessing dosing and treatment effects on brain metabolism and cognition